
Press Release

1 March 2021

Immunicum AB (publ) Announces Appointment of Jeroen Rovers as Chief Medical Officer

Immunicum AB (publ; IMMU.ST) announced today that Jeroen Rovers, M.D., Ph.D., has been appointed to the position of Chief Medical Officer (CMO). The appointment is effective today. Dr. Rovers transitions from his role as Managing Director of DCprime and continues to serve on Immunicum's management team. Peter Suenart, M.D., Ph.D., current CMO of Immunicum, will remain with the Company as clinical advisor, continuing to support the clinical development team and ensuring a smooth transition process.

"Jeroen has over 20 years of experience in pioneering innovative cell therapies and late-stage drug development, which will be invaluable to Immunicum as we advance our expanded pipeline through the next phases of development," stated Sven Rohmann, M.D., Ph.D., CEO of Immunicum. "On behalf of the Company, I would like to thank Peter for his significant contributions to ilixadencel's progress to date. He has successfully delivered results from the Phase II MERECA trial and Phase I/II trials in HCC and GIST, while initiating the ongoing Phase Ib/II ILIAD trial in combination with checkpoint inhibitors, and has been instrumental in the recent regulatory successes for ilixadencel. We look forward to Peter's continued insights on advancing ilixadencel and the pipeline in his role as clinical advisor to Immunicum."

Dr. Rovers joined DCprime as Chief Medical Officer at the end of 2018 and has been serving as Managing Director for DCprime following the business combination with Immunicum in December of last year. Prior to DCprime, he was Chief Medical Officer at Kiadis, a company focused on developing cell-based immunotherapies. As part of the management team at Kiadis, he brought the company public through an IPO. Before Kiadis, Dr. Rovers held Chief Medical Officer and senior clinical development positions at Ceronco Biosciences and Dutch biotechnology company Organon, prior to its acquisition by MSD. Earlier in his career, he held senior positions at Wyeth Pharmaceuticals and Biolitec Pharma Ltd. Dr. Rovers trained as a pharmaceutical physician at the European Center of Pharmaceutical Medicine in Basel, Switzerland; he obtained his M.D. and Ph.D. in Medicine from Leiden University, the Netherlands.

FOR MORE INFORMATION, PLEASE CONTACT:

Sven Rohmann, M.D., Ph.D., CEO
Telephone: +46 8 732 8400
E-mail: info@immunicum.com

INVESTOR RELATIONS

Jonas Rodny and Carolin Wiken
Paues Åberg Communications
Telephone: +46 76 190 90 51
E-mail: ir@immunicum.com

MEDIA RELATIONS

Eva Mulder and Sophia Hergenhan, Ph.D.
Trophic Communications
Telephone: +49 175 222 57 56
E-mail: ir@immunicum.com

ABOUT IMMUNICUM AB (PUBL)

Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer

relapse vaccination, the company aims to improve survival outcomes and quality of life for a broad population of cancer patients. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com